The effect of rosuvastatin on liver color ultrasound, ALT, AST and γ-GGT of nonalcoholic fatty liver disease
-
摘要: [目的]探讨他汀治疗非酒精性脂肪性肝病的疗效及安全性。[方法]选取我院2016年1月~2017年6月存在血脂异常，ALT、AST为正常上限的1~3倍，γ-GGT为正常上限1~5倍的非酒精性脂肪肝性肝病患者共42例，治疗前至少予一次肝脏彩超确认为脂肪肝，至少3个月内两次确认肝酶异常，肝酶确认水平取平均值，告知相关注意事项，予瑞舒伐他汀（可定）10 mg，每晚1次服用，观察治疗后1个月、3个月、6个月的肝酶情况，观察3个月、6个月肝脏彩超情况，并观察不良反应。[结果]治疗后1个月肝酶变化无明显差异，治疗后3个月、6个月肝酶明显下降，差异有统计学意义；治疗后3个月肝脏超声变化无明显差异性，6个月肝脏彩超提示脂肪肝程度明显减轻，差异有统计学意义。[结论]伴肝功能轻度升高的NAFLD患者使用瑞舒伐他汀是安全的，瑞舒伐他汀不引起NAFLD患者的转氨酶异常升高，瑞舒伐他汀能改善NAFLD患者肝功能及脂肪变性。Abstract: [Objective] To investigate the clinical efficacy and safety of Rosuvastatin in the treatment of nonalcoholic fatty liver disease(NAFLD).[Methods] A total of 42 cases of patients with NAFLD admitted to our hospital from January 2016 to June 2017, who had dyslipidemia and whose ALT and AST levels were 1-3 times the upper normal limit and γ-GGT level was 1-5 times the upper normal limit, were selected in this study.Before treatment, the patients were performed liver color ultrasound at least once to make a definite diagnosis of fatty liver, and were diagnosed with abnormal liver enzyme at least twice within three months.The liver enzyme confirmation level took the average, and the patients were informed relevant matters needing attention.Then the patients were given 10 mg Rosuvastatin(Crestor) once every night.In 1 month, 3 months and 6 months after the treatment, the liver enzyme of the patients was observed, in 3 months and 6 months after the treatment, the liver color ultrasound of the patients was observed, and the adverse reactions were observed.[Results] There was no significant difference in the change of liver enzyme in 1 month after the treatment.In 3 months and 6 months after the treatment, the level of liver enzyme declined dramatically, and the difference was statistically significant;in 3 months after the treatment, there was no significant difference in the change of liver color ultrasound.In 6 months after the treatment, the result of liver color ultrasound showed that the degree of fatty liver was significantly relieved, and the difference was statistically significant.[Conclusion] Rosuvastatin is safe in treating NAFLD patients with mild liver dysfunction.Rosuvastatin does not cause abnormal increase of aminopherase in NAFLD patients and can improve liver function and steatosis of NAFLD patients.
-
Key words:
- Rosuvastatin /
- Fatty liver /
- γ-GGT /
- Metabolic syndrome
-
-
[1] 赵文霞.如何改善非酒精性脂肪性肝炎患者的肝功能[J].世界华人消化杂志, 2010, 18(14):1461-1464.
[2] Norton J.Greenberger著(美).胃肠病学、肝脏病学与内镜学最新诊断和治疗.2版.陈世耀, 沙卫红译[M].天津:天津科技翻译出版有限公司, 2016:570-576.
[3] 刘怀昌, 肖磊, 徐智立, 等.他汀类降脂药联合胰岛素增敏剂对非酒精性脂肪肝的疗效及动脉弹性的影响[J].中国现代医学杂志, 2015, 25(17):82-85.
[4] 李玉, 方群, 戴加乐, 等.阿托伐他汀治疗老年非酒精性脂肪肝的患者疗效及对血清IL-6、TNF-α水平的影响[J].中国中西医结合消化杂志, 2015, 23(12):893-894.
[5] 陈思, 赵金珍, 胡晶, 等.他汀类药物在治疗非酒精性脂肪肝病中的研究进展[J].中国动脉硬化杂志, 2017, 25(3):297-302.
[6] 戴雅玥, 邵琳琳, 冯文焕.他汀类药物对非酒精性脂肪性肝病的治疗作用[J].东南大学学报(医学版), 2013, 32(1):94-97.
[7] 钱家鸣.消化内科学[M].2版.北京:人民卫生出版社, 2014:227-233.
[8] 汪江波, 袁旭, 张瑞, 等.非酒精性脂肪肝发病机制的研究进展[J].现代医药卫生, 2017, 33(15):2284-2288.
[9] 林三仁.消化内科学高级教程[M].北京:人民军医出版社, 2009:361-365.
[10] 廖敏辉, 刘永刚, 张国祥, 等.他汀类药物引起转氨酶升高的研究进展[J].解放军药学学报, 2015, 31(2):158-160.
[11] Rinella M F.Nonalcuholic fatty liver disease[J].JAMA, 2015, 313(22):2262-2263.
[12] 徐太军.动脉粥样硬化患者C-反应蛋白、低密度脂蛋白与非酒精性脂肪肝的相关性研究[J].中国中西医结合消化杂志, 2016, 24(10):748-750.
[13] Athyros VG, Tziomalos K, Gossios TD, et al.Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation Study:apost-hoc analysis[J].The Lanc et, 2010, 376(9756):1916-1922.
[14] Jacobson T A, Ito M K, Maki K C, et al.National lipid association recommendations for patient-centered management of dyslipidemia:part 1-full report[J].J Clin Lipidol, 2015, 9(2):129-169.
[15] 李荣, 赵志刚, 司延斌.他汀类药物肝脏安全性的研究进展及合理选用[J].药品评价, 2013, 10(4):36-41.
-
计量
- 文章访问数: 769
- PDF下载数: 626
- 施引文献: 0
下载: